
==== Front
BMC Endocr Disord
BMC Endocr Disord
BMC Endocrine Disorders
1472-6823
BioMed Central London

1712
10.1186/s12902-024-01712-3
Research
Adrenal insufficiency and the use of mineralocorticoid treatment in male patients with adrenoleukodystrophy; a retrospective analysis of an institutional database
Zekarias Kidmealem L kzekaria@umn.edu

1
Salim Michael 1
Tessier Katelyn M 2
Radulescu Angela 1
1 https://ror.org/017zqws13 grid.17635.36 0000 0004 1936 8657 Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, 420 Delaware St SE, MMC 101, Minneapolis, MN 55455 USA
2 grid.17635.36 0000000419368657 Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, USA
9 9 2024
9 9 2024
2024
24 18117 5 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Introduction

Adrenoleukodystrophy (ALD) patients exhibit three primary clinical phenotypes: primary adrenal insufficiency, adrenomyeloneuropathy, and cerebral demyelination due to the accumulation of saturated very long-chain fatty acids in the adrenal cortex and central nervous system white matter and axons. We investigated the diagnosis of adrenal insufficiency (AI) and the use of mineralocorticoid treatment in male ALD patients.

Methods

A retrospective chart review of electronic medical records was conducted for all ALD patients at a single institution between January 1, 2011, and December 6, 2021.

Results

Among the 437 ALD patients, 82% were male and 18% were female. Of the male ALD patients, 60% (213 out of 358) had a diagnosis of AI, and 39% (84 out of 213) of those with AI were prescribed mineralocorticoid replacement therapy.

Conclusion

AI is highly prevalent among ALD patients, with approximately 40% of those with a diagnosis of AI undergoing mineralocorticoid replacement therapy. Further research is warranted to delineate the characteristics of patients predisposed to developing mineralocorticoid deficiency within the context of ALD and AI.

Keywords

Adrenoleukodystrophy
Neurodegenerative disorder
Adrenal insufficiency
Mineralocorticoid deficiency
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Adrenoleukodystrophy (ALD) is a neurodegenerative disorder that affects both the white matter and axons of the central nervous system, as well as the adrenal cortex, due to the accumulation of saturated very long-chain fatty acids (VLCFA)( [1–3]. It is an X-linked inherited disorder caused by a defective gene, ABCD1, located on Xq28 [2]. The defective gene causes the accumulation of very long-chain fatty acids (VLCFA) in plasma and tissues, including the white matter of the brain, spinal cord, and adrenal cortex. This buildup of VLCFA in the zona fasciculata and reticularis of the adrenal cortex, while relatively sparing the zona glomerulosa, is thought to contribute to the development of primary adrenal insufficiency [4–7].

Male patients with ALD typically manifest three primary clinical phenotypes: adrenal insufficiency (AI), adrenomyeloneuropathy (AMN), and cerebral demyelination (cerebral ALD) [2, 8]. While progressive spinal cord disease can develop in women with ALD, AI and cerebral ALD are rare in this population, occurring in less than 1% of cases [4–6]. This X-linked inherited disorder primarily affects men, while women are mostly carriers and tend to develop mild clinical manifestations after the age of 60 [6, 7].

A study reported a lifetime prevalence of adrenal insufficiency in male ALD patients of approximately 80% [7]. In this study, the median time to the onset of adrenal insufficiency was 14 years (95% CI, 9.70 to 18.30 years) and the cumulative proportion of patients developing adrenal insufficiency varied by age group, being highest in early childhood: 46.8% (SEM 0.041%) for ages 0 to 10 years, 28.6% (SEM 0.037%) for ages 11 to 40 years, and 5.6% (SEM 0.038%) for those over 40 years [7]. This underscores the importance of age-based regular screening for AI in this demographic.

Elevated adrenocorticotropic hormone (ACTH) and impaired cortisol response to ACTH administration are the primary biochemical indicators of primary AI, often preceding clinical symptoms by two years [9, 10]. As VLCFAs primarily accumulate in the zona fasciculata and reticularis, the relative preservation of the zona glomerulosa explains why most patients with adrenal insufficiency do not develop mineralocorticoid deficiency [6, 7]. Mineralocorticoid deficiency is reported in 40% of patients with ALD [6].

Methods

The University of Minnesota’s Adrenoleukodystrophy Comprehensive Clinic is one of the leading centers worldwide for the assessment and treatment of ALD patients. Among the 152 transplant centers for ALD, the University of Minnesota accounts for 38% of the contributions, while the remaining 151 centers collectively contribute 62%. Most patients undergoing their initial evaluation and diagnosis at their respective institutions.

We conducted a retrospective analysis of electronic medical records (EMR) at the University of Minnesota spanning from January 1, 2011, to December 6, 2021, encompassing all patients diagnosed with ALD. Approval for the study protocol (Study00014492) was obtained from the Institutional Review Board. Data extraction was facilitated by the informatics consulting services of the Clinical and Translational Science Institute and securely maintained within the Academic Health Center Secure Data Environment. The study included only individuals who had given their consent to use their data for research purposes.

All patients who provided consent for EMR research were included. Age and self-report race and ethnicity data were obtained from patients’ EMR. Individual chart reviews were performed to confirm ALD diagnoses utilizing VLCFA results, genetic assessments, or documented diagnoses in medical history or visit notes. Diagnosis of AI was ascertained through thorough chart reviews, confirming documented diagnoses in medical history or progress notes. We reviewed glucocorticoid medications, including both oral and injectable forms. The use of mineralocorticoids was determined by whether fludrocortisone was prescribed. Although cortisol, ACTH, aldosterone, and renin levels were assessed, most patients did not have these lab results recorded in their EMR. These labs might have been completed at their initial evaluation and diagnosis at their respective institutions prior to referral to the University of Minnesota. The authors didn’t have access to laboratory and other assessment completed outside of University of Minnesota.

Statistical method

Demographic data for all ALD patients and those with AI were summarized using descriptive statistics. To investigate the association between demographics and AI, Wilcoxon rank-sum tests for continuous variables and Chi-square or Fisher’s exact tests for categorical variables. Glucocorticoid use was also summarized. Data analysis was conducted using R (version 4.1.2, R Core Team) [11].

Results

Out of 437 patients with ALD, 82% (358/437) were males and 18% (79/437) were females. Table 1 provides demographic details of male patients with ALD and by diagnosis of AI. The median age among male patients with ALD was 14, ranging from 0 to 92 years. There was a significant difference in median age for those with and without diagnosis of AI on their medical chart (16 vs. 11 p < 0.001). No differences were seen for self-reported race and ethnicity.

Table 1 Male patients with adrenoleukodystrophy: comparison of demographics by adrenal insufficiency (AI)

Variable	All ALD2 male patients (N = 358)	Diagnosis of AI3 (N = 213)	No diagnosis of AI2 (N = 145)	P-value1	
Age, median (range)	14.0 (0.0, 92.0)	16.0 (1.0, 68.0)	11.0 (0.0, 92.0)	< 0.001	
Race4, n (%)				0.540	
 White	231 (64.5%)	142 (66.7%)	89 (61.4%)	
 Asian	20 (5.6%)	10 (4.7%)	10 (6.9%)	
 American Indian or Alaska Native	6 (1.7%)	2 (0.9%)	4 (2.8%)	
 More than 1 race	3 (0.8%)	2 (0.9%)	1 (0.7%)	
 Unknown	98 (27.4%)	57 (26.8%)	41 (28.3%)	
Ethnicity4, n (%)				0.154	
 Hispanic or Latino	28 (7.8%)	15 (7.0%)	13 (9.0%)	
 Not Hispanic or Latino	266 (74.3%)	166 (77.9%)	100 (69.0%)	
 Unknown	64 (17.9%)	32 (15.0%)	32 (22.1%)	
1Wilcoxon rank-sum test was used for age. Chi-square or Fisher’s exact tests were used for categorical variables. 2ALD: Adrenoleukodystrophy; 3AI: adrenal insufficiency; 4Race and ethnicity are self-report

60% (213/358) of male patients with ALD had a diagnosis of AI mentioned on their chart. 39% (84/213) of patients with AI and ALD were on mineralocorticoid replacement therapy, fludrocortisone at the dose of 0.05-01 mg per day.

Table 2 provides details on adrenal insufficiency diagnosis and fludrocortisone use. Cortisol and renin labs were available for 62% (220/358) and 50% (179/358) of patients with ALD, respectively. Glucocorticoid medications prescribed for patients with AI and ALD included hydrocortisone (190/213), prednisone (38/213), dexamethasone (66/213), and other (33/213). 7% (15/213) patients did have the diagnosis of AI but didn’t have glucocorticoid medications prescribed. 39% of (56/145) those without a diagnosis of AI on their chart were prescribed glucocorticoid medication. Table 3 describes glucocorticoid use by adrenal insufficiency diagnosis for all male ALD patients.

Table 2 Summary of diagnosis of adrenal insufficiency and fludrocortisone use for male ALD1 patients

Variable	All male ALD1 patients (N = 358)	
Adrenal insufficiency, n (%)	213 (59.5%)	
Fludrocortisone, n (%)	84 (23.5%)	
1ALD: Adrenoleukodystrophy

Table 3 Glucocorticoid use by adrenal insufficiency diagnosis for all male ALD patients

Variable	All ALD1 patients
(N = 358)	AI2
(N = 213)	No AI2
(N = 145)	
Hydrocortisone, n (%)	225 (62.8%)	190 (89.2%)	35 (24.1%)	
Prednisone, n (%)	46 (12.8%)	38 (17.8%)	8 (5.5%)	
Dexamethasone, n (%)	101 (28.2%)	66 (31.0%)	35 (24.1%)	
Other, n (%)	41 (11.5%)	33 (15.5%)	8 (5.5%)	
Any medications, n (%)	254 (70.9%)	198 (93.0%)	56 (38.6%)	
1ALD: Adrenoleukodystrophy; 2AI: adrenal insufficiency

Discussion

This chart review study, utilizing EMR data, provides a descriptive analysis of AI prevalence among ALD patients and the utilization of mineralocorticoid therapy in this group. Our findings suggest a lower AI prevalence compared to studies relying on biochemical evidence, potentially because biochemical abnormalities precede clinical symptoms by two years [7, 9, 10]. Furthermore, the introduction of newborn screening programs for ALD, recommended by the US Department of Health and Human Services, has been underway in recent years [12]. This might have led to a larger population of young ALD patients who have not yet developed AI.

Approximately 40% of AI and ALD patients received mineralocorticoid replacement therapy, which could be due to the preferential VLCFA accumulation in the zona reticularis and zona fasciculata of the adrenal cortex, while sparing the zona glomerulosa [13]. The treatment of adrenal insufficiency in patients with adrenoleukodystrophy (ALD) is similar to other patients with primary adrenal insufficiency, involving the replacement of glucocorticoids. However, unlike other patients with primary adrenal insufficiency, those with ALD may not always require mineralocorticoid replacement, as the loss of mineralocorticoid function is not universal in these patients.

While our study benefits from a large patient database, AI diagnosis based on medical chart documentation rather than biochemical evidence may underestimate prevalence. We were unable to assess and include ACTH, cortisol, aldosterone, renin, sodium, potassium, and ACTH stimulation tests in this study, as suggested by the reviewers, because these lab results were not available for the majority of patients in our EMR system.

In conclusion, AI prevalence remains high among male ALD patients, with approximately 40% of those with both conditions receiving mineralocorticoid replacement therapy. Our study represents the second attempt to quantify mineralocorticoid treatment prevalence in males diagnosed with both ALD and AI. Further research is necessary to identify individuals at risk of developing mineralocorticoid deficiency in the context of ALD and AI.

Acknowledgements

Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UM1TR004405. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the University Q9 of Minnesota.

Author contributions

Kidmealem L Zekarias - Data analysis & interpretation, wrote the main manuscript text and revised manuscript. Michael Salim - Data acquisition, analysis and interpretation and revised manuscript. Katelyn M Tessier - Data analysis, interpretation and revised manuscript. Angela Radulescu - Data acquisition, analysis and interpretation and revised manuscript.All authors reviewed the manuscript.

Funding

Not applicable.

Data availability

Data is provided within the manuscript. In order to protect the privacy of study participants, the detailed data cannot be shared openly. We are committed to maintaining the confidentiality and anonymity of our participants, and therefore, the data is subject to restrictions on public access.

Declarations

Ethics approval and consent to participate

Approval for the study protocol (Study00014492) was obtained from the Institutional Review Board (IRB) of University of Minnesota. The IRB determined that the study meets the criteria for ‘consent is not required.’ Obtaining consent from all participants was not applicable to this study. Data extraction was completed only for those participants who had consented to the use of their data for research purposes. Data extraction was facilitated by the informatics consulting services of the Clinical and Translational Science Institute and securely maintained within the Academic Health Center Secure Data Environment. The study included only individuals who had given their consent to use their data for research purposes.

Consent for publication

Not applicable.

Conflict of interest

The authors have no conflicts of interest to disclose.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Engelen M Kemp S de Visser M van Geel BM Wanders RJ Aubourg P X-linked adrenoleukodystrophy (ALD): clinical presentation and guidelines for diagnosis, follow-up and management Orphanet J Rare Dis 2012 7 51 10.1186/1750-1172-7-51 22889154
Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P. X-linked adrenoleukodystrophy (ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51.22889154 10.1186/1750-1172-7-51
2. Kemp S Huffnagel IC Linthorst GE Wanders RJ Engelen M Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history Nat Rev Endocrinol 2016 12 10 606 15 10.1038/nrendo.2016.90 27312864
Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engelen M. Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol. 2016;12(10):606–15.27312864 10.1038/nrendo.2016.90
3. Wanders RJ van Roermund CW Lageweg W Jakobs BS Schutgens RB Nijenhuis AA X-linked adrenoleukodystrophy: biochemical diagnosis and enzyme defect J Inherit Metab Dis 1992 15 4 634 44 10.1007/BF01799620 1528022
Wanders RJ, van Roermund CW, Lageweg W, Jakobs BS, Schutgens RB, Nijenhuis AA, et al. X-linked adrenoleukodystrophy: biochemical diagnosis and enzyme defect. J Inherit Metab Dis. 1992;15(4):634–44.1528022 10.1007/BF01799620
4. Huffnagel IC Dijkgraaf MGW Janssens GE van Weeghel M van Geel BM Disease progression in women with X-linked adrenoleukodystrophy is slow Orphanet J Rare Dis 2019 14 1 30 10.1186/s13023-019-1008-6 30732635
Huffnagel IC, Dijkgraaf MGW, Janssens GE, van Weeghel M, van Geel BM, et al. Disease progression in women with X-linked adrenoleukodystrophy is slow. Orphanet J Rare Dis. 2019;14(1):30.30732635 10.1186/s13023-019-1008-6
5. Engelen M Barbier M Dijkstra IM Schur R de Bie RM Verhamme C X-linked adrenoleukodystrophy in women: a cross-sectional cohort study Brain 2014 137 693 706 10.1093/brain/awt361 24480483
Engelen M, Barbier M, Dijkstra IM, Schur R, de Bie RM, Verhamme C, et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain. 2014;137:693–706.24480483 10.1093/brain/awt361
6. Alcantara JR Grant NR Sethuram S Early detection of adrenal insufficiency: the impact of Newborn Screening for Adrenoleukodystrophy J Clin Endocrinol Metab 2023 108 11 1306 15 10.1210/clinem/dgad286
Alcantara JR, Grant NR, Sethuram S, et al. Early detection of adrenal insufficiency: the impact of Newborn Screening for Adrenoleukodystrophy. J Clin Endocrinol Metab. 2023;108(11):1306–15.10.1210/clinem/dgad286
7. Huffnagel IC Laheji FK Aziz-Bose R Tritos NA Marino R Linthorst GE The natural history of adrenal insufficiency in X-Linked adrenoleukodystrophy: an international collaboration J Clin Endocrinol Metab 2019 104 1 118 26 10.1210/jc.2018-01307 30252065
Huffnagel IC, Laheji FK, Aziz-Bose R, Tritos NA, Marino R, Linthorst GE, et al. The natural history of adrenal insufficiency in X-Linked adrenoleukodystrophy: an international collaboration. J Clin Endocrinol Metab. 2019;104(1):118–26.30252065 10.1210/jc.2018-01307
8. Galea E, Launay N, Portero-Otin M, Ruiz M, Pamplona R, Aubourg P et al. Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases? Biochim Biophys Acta. 2012; 1822(9).
9. Blevins LS Shankroff J Moser HW Ladenson PW Elevated plasma adrenocorticotropin concentration as evidence of limited adrenocortical reserve in patients with adrenomyeloneuropathy J Clin Endocrinol Metab 1994 78 2 261 5 8106609
Blevins LS, Shankroff J, Moser HW, Ladenson PW. Elevated plasma adrenocorticotropin concentration as evidence of limited adrenocortical reserve in patients with adrenomyeloneuropathy. J Clin Endocrinol Metab. 1994;78(2):261–5.8106609
10. Dubey P Raymond GV Moser AB Kharkar S Bezman L Moser HW Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening J Pediatr 2005 146 4 528 32 10.1016/j.jpeds.2004.10.067 15812458
Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr. 2005;146(4):528–32.15812458 10.1016/j.jpeds.2004.10.067
11. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021. https://www.R-project.org/
12. Kemper AR Brosco J Comeau AM Green NS Grosse SD Jones E Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation Genet Med 2017 19 1 121 6 10.1038/gim.2016.68 27337030
Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E, et al. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genet Med. 2017;19(1):121–6.27337030 10.1038/gim.2016.68
13. Cappa M Todisco T Bizzarri C X-linked adrenoleukodystrophy and primary adrenal insufficiency Front Endocrinol (Lausanne) 2023 14 1309053 10.3389/fendo.2023.1309053 38034003
Cappa M, Todisco T, Bizzarri C. X-linked adrenoleukodystrophy and primary adrenal insufficiency. Front Endocrinol (Lausanne). 2023;14:1309053.38034003 10.3389/fendo.2023.1309053
